<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097223</url>
  </required_header>
  <id_info>
    <org_study_id>1237-0092</org_study_id>
    <nct_id>NCT04097223</nct_id>
  </id_info>
  <brief_title>A Study Based on Health Insurance Data About the Treatment of Patients Who Have Been Newly Diagnosed With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Real-world Treatment of Newly Diagnosed COPD Patients: A Retrospective German Claims Data Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective analysis study in COPD patients for an exact follow-up period of 12 months
      (in subgroup analyses: 24 and 36 months); censoring of patients will only be done in case a
      patient died during the respective follow-up period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Actual">June 5, 2020</completion_date>
  <primary_completion_date type="Actual">June 5, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of COPD</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of treatment of COPD-12 and COPD diseases management program (DMP)-12 patients with two versions of German treatment guidelines (2012/2018)</measure>
    <time_frame>At index date</time_frame>
    <description>All incident COPD patients with a follow-up of 12 months since index date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of treatment of COPD-12 and COPD diseases management program (DMP)-12 patients with two versions of German treatment guidelines (2012/2018)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>All incident COPD patients with available DMP data (at least one entry during 3 months after index date) and a follow-up of 12 months since index date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of exacerbation</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment costs of COPD patients, other medications, Outpatient treatment, Hospitalizations, Long-Term Oxygen Therapy (LTOT)</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">40000</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Subjects with Pulmonary Disease, Chronic Obstructive</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Long-acting beta agonist + Long-acting muscarinic antagonist</intervention_name>
    <description>drug</description>
    <arm_group_label>Subjects with Pulmonary Disease, Chronic Obstructive</arm_group_label>
    <other_name>Olodaterol and tiotropium bromide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Long-acting beta agonist + Long-acting muscarinic antagonist+Inhaled corticosteriods</intervention_name>
    <description>drug</description>
    <arm_group_label>Subjects with Pulmonary Disease, Chronic Obstructive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A retrospective analysis of patients with Chronic Obstructive Pulmonary Disease (COPD)
        based on current German COPD guidleines.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients who were continuously insured by the sickness fund for the entire period
             (01/01/2013-30/06/2018) or, in case a patient deceased after index date, for the time
             until death

          -  A patient will be included as an incident COPD patient if either a hospital documented
             at least one COPD diagnosis (International Statistical Classification of Diseases and
             Related Health Problems (ICD-10 J 44.-) or a specialist (pneumologist) documented at
             least 2 confirmed COPD diagnoses (above ICD-10) code) in two different quarters; the
             first of the above diagnoses is defined as index diagnosis; inclusion period is
             defined as lasting from 01/01/2014 until 30/06/2017

          -  Patients should not have received any COPD diagnosis (ICD-10 J44.-) or any
             COPD-associated medication in the 12 months pre-index period

          -  Patient should have, at date of incident COPD diagnosis (index date), an age of at
             least 40 years

        Exclusion Criteria:

          -  Patients received , at least one confirmed inpatient asthma diagnosis or two confirmed
             outpatient diagnoses of asthma (ICD-10: J45) by pneumologists
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute for pharmacoeconomics and pharmaceutical logistics e.V (IPAM)</name>
      <address>
        <city>Wismar</city>
        <zip>23966</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
    <mesh_term>Cholinergic Agents</mesh_term>
    <mesh_term>Muscarinic Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://trials.boehringer‐ingelheim.com/trial_results/clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.
Also, Researchers can use the following link http://trials.boehringer-ingelheim.com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the Research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned Analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://trials.boehringer‐ingelheim.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

